Standard
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. / Sorensen, Per Soelberg; Ross, Christian; Clemmesen, Katja Maria; Bendtzen, Klaus; Frederiksen, Jette Lautrup; Jensen, Kai; Kristensen, Ole; Petersen, Thor; Rasmussen, Soren; Ravnborg, Mads; Stenager, Egon; Koch-Henriksen, Nils; Danish Multiple Sclerosis Study Group.
I:
Lancet, Bind 362, Nr. 9391, 11.10.2003, s. 1184-91.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Sorensen, PS
, Ross, C, Clemmesen, KM, Bendtzen, K
, Frederiksen, JL, Jensen, K, Kristensen, O, Petersen, T, Rasmussen, S, Ravnborg, M, Stenager, E, Koch-Henriksen, N & Danish Multiple Sclerosis Study Group 2003, '
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis',
Lancet, bind 362, nr. 9391, s. 1184-91.
https://doi.org/10.1016/S0140-6736(03)14541-2APA
Sorensen, P. S.
, Ross, C., Clemmesen, K. M., Bendtzen, K.
, Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., Stenager, E., Koch-Henriksen, N., & Danish Multiple Sclerosis Study Group (2003).
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Lancet,
362(9391), 1184-91.
https://doi.org/10.1016/S0140-6736(03)14541-2Vancouver
Sorensen PS
, Ross C, Clemmesen KM, Bendtzen K
, Frederiksen JL, Jensen K o.a.
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Lancet. 2003 okt. 11;362(9391):1184-91.
https://doi.org/10.1016/S0140-6736(03)14541-2Author
Sorensen, Per Soelberg ; Ross, Christian ; Clemmesen, Katja Maria ; Bendtzen, Klaus ; Frederiksen, Jette Lautrup ; Jensen, Kai ; Kristensen, Ole ; Petersen, Thor ; Rasmussen, Soren ; Ravnborg, Mads ; Stenager, Egon ; Koch-Henriksen, Nils ; Danish Multiple Sclerosis Study Group. / Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. I: Lancet. 2003 ; Bind 362, Nr. 9391. s. 1184-91.
Bibtex
@article{dabcb64c240a4744b70e5a65c51c2ada,
title = "Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis",
abstract = "Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.",
author = "Sorensen, {Per Soelberg} and Christian Ross and Clemmesen, {Katja Maria} and Klaus Bendtzen and Frederiksen, {Jette Lautrup} and Kai Jensen and Ole Kristensen and Thor Petersen and Soren Rasmussen and Mads Ravnborg and Egon Stenager and Nils Koch-Henriksen and Clemmesen, {Katja Maria}",
year = "2003",
month = oct,
day = "11",
doi = "http://dx.doi.org/10.1016/S0140-6736(03)14541-2",
language = "English",
volume = "362",
pages = "1184--91",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9391",
}
RIS
TY - JOUR
T1 - Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
AU - Sorensen, Per Soelberg
AU - Ross, Christian
AU - Clemmesen, Katja Maria
AU - Bendtzen, Klaus
AU - Frederiksen, Jette Lautrup
AU - Jensen, Kai
AU - Kristensen, Ole
AU - Petersen, Thor
AU - Rasmussen, Soren
AU - Ravnborg, Mads
AU - Stenager, Egon
AU - Koch-Henriksen, Nils
AU - Danish Multiple Sclerosis Study Group
PY - 2003/10/11
Y1 - 2003/10/11
N2 - Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
AB - Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
U2 - http://dx.doi.org/10.1016/S0140-6736(03)14541-2
DO - http://dx.doi.org/10.1016/S0140-6736(03)14541-2
M3 - Journal article
VL - 362
SP - 1184
EP - 1191
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9391
ER -
